A Phase IIa Study of ANAVEX2-73 Adaptive-Trial-Design with Repeated Doses, Maximum Tolerated Dose Finding, Pharmacodynamic Investigation and Bioavailability Evaluation in Patients with Mild to Moderate Alzheimer’s Disease With a 6-Month Open Label Follow-Up Period.
New Takeda AD-4833 TOMM40_303 Study - extension study.
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer’s Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD...
A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease (Prodromal AD).
A multicentre, randomised, double-blind, placebo-controlled, Phase 2 study comparing 3mg and 12mg of LY3202626 with placebo over 52 weeks in approximately 500 patients with mild Alzheimer’s disease dementia (NAVIGATE-AD).
A Randomized, Double-Blind, Placebo-Controlled, Phase I Study Of The Safety And Pharmacokinetics Of Two Doses Of Ct1812 In Subjects With Mild To Moderate Alzheimer’s Disease.
Astra Zeneca, D5010C00009, A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Outpatients with Early Alzheimer’s Disease; PAREXEL number 216846.
A clinical trial to determine the safety and efficacy of MK-8931 in Mild to Moderate Alzheimer’s Disease. (EPOCH).
'Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) versus Placebo.
Randomised, double-blind, parallel-group, placebo-controlled study of Lu AE58054 in patients with mild-moderate Alzheimer’s disease treated with an acetylcholinesterase inhibitor; Study 3.